Adjunct to diet for the treatment of patients w/ elevated total cholesterol, LDL-cholesterol, apolipoprotein B & triglycerides; increase HDL-cholesterol in patients w/ primary hypercholesterolemia (heterozygous familial & non-familial hypercholesterolemia), combined (mixed) hyperlipidemia (Fredrickson Types IIa & IIb), elevated serum TG levels (Fredrickson Type IV); dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Reduction of total cholesterol & LDL-cholesterol in patients w/ homozygous familial hypercholesterolemia. Reduce risk of fatal CHD & non-fatal MI, stroke, revascularization procedures & angina pectoris in patients w/o clinically evident CV disease & w/ or w/o dyslipidemia but w/ multiple risk factors for CHD. Reduce risk of non-fatal MI, fatal & non-fatal stroke, revascularization procedures, hospitalization for CHF & angina in patients w/ clinically evident CHD. Reduce risk of CV disease in patients w/ diabetes w/ moderately decreased eGFR. Reduce risk of major CV events (including stroke) in patients w/ clinically evident CHD & chronic kidney disease not requiring dialysis. Reduce rate of GFR decline & progression of chronic kidney disease in patients w/ clinically evident CHD &/or diabetes w/ microalbuminuria. Adjunct to diet to reduce total cholesterol, LDL-cholesterol & apolipoprotein B levels in boy & post-menarchal girls 10-17 yr w/ heterozygous familial hypercholesterolemia.